Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells

Cancer Letters

Volumn 321, Issue 2, 2012, Pages 120-127

  Abu Yousif, Adnan O ^a   Moor, Anne C E ^a,b   Zheng, Xiang ^a,c   Savellano, Mark D ^a,d   Yu, Weiping ^a,e   Selbo, Pål K ^a   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Photonamic GmbH and Co KG   (Germany)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cetuximab; Immunoconjugate; Ovarian cancer; Photodynamic therapy; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG FORMULATION; DRUG PURITY; DRUG TARGETING; HUMAN; HUMAN CELL; NONHUMAN; OVARY CANCER; PHOTOTOXICITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DERMATITIS, PHOTOTOXIC; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84860920745     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.014     Document Type: Article

References (59)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Allison R.R., Zervos E., Sibata C.H. Cholangiocarcinoma: an emerging indication for photodynamic therapy. Photodiagn. Photodyn. Ther. 2009, 6:84-92.
3. Fan B.G., Andren-Sandberg A. Photodynamic therapy for pancreatic cancer. Pancreas 2007, 34:385-389.
4. Ross P., Grecula J., Bekaii-Saab T., Villalona-Calero M., Otterson G., Magro C. Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Lasers Surg. Med. 2006, 38:881-889.
5. Biel M.A. Photodynamic therapy of head and neck cancers. Methods Mol. Biol. 2011, 635:281-293.
6. Ortel B., Shea C.R., Calzavara-Pinton P. Molecular mechanisms of photodynamic therapy. Front Biosci. 2009, 14:4157-4172.
7. Duska L.R., Hamblin M.R., Miller J.L., Hasan T. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J. Natl. Cancer Inst. 1999, 91:1557-1563.
8. Kessel D. Death pathways associated with photodynamic therapy. Med. Laser Appl. 2006, 21:219-224.
9. Kessel D. Promotion of PDT efficacy by a Bcl-2 antagonist. Photochem. Photobiol. 2008, 84:809-814.
10. Hasan T., Ortel B., Solban N., Pogue B. Photodynamic Therapy of Cancer 2006, B.C. Decker Inc., Hamilton, Ontario.
11. Hahn S.M., Fraker D.L., Mick R., Metz J., Busch T.M., Smith D., Zhu T., Rodriguez C., Dimofte A., Spitz F., Putt M., Rubin S.C., Menon C., Wang H.W., Shin D., Yodh A., Glatstein E. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin. Cancer Res. 2006, 12:2517-2525.
12. Hendren S.K., Hahn S.M., Spitz F.R., Bauer T.W., Rubin S.C., Zhu T., Glatstein E., Fraker D.L. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann. Surg. Oncol. 2001, 8:65-71.
13. DeLaney T.F., Sindelar W.F., Tochner Z., Smith P.D., Friauf W.S., Thomas G., Dachowski L., Cole J.W., Steinberg S.M., Glatstein E. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int. J. Radiat. Oncol. Biol. Phys. 1993, 25:445-457.
14. Wilson J.J., Jones H., Burock M., Smith D., Fraker D.L., Metz J., Glatstein E., Hahn S.M. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int. J. Oncol. 2004, 24:711-717.
15. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 2006, 33:369-385.
16. Capdevila J., Elez E., Macarulla T., Ramos F.J., Ruiz-Echarri M., Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat. Rev. 2009, 35:354-363.
17. Martinez-Carpio P.A., Trelles M.A. The role of epidermal growth factor receptor in photodynamic therapy: a review of the literature and proposal for future investigation. Lasers Med. Sci. 2010, 25:767-771.
18. del Carmen M.G., Rizvi I., Chang Y., Moor A.C., Oliva E., Sherwood M., Pogue B., Hasan T. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J. Natl. Cancer Inst. 2005, 97:1516-1524.
19. R. Lewis, L. Schuman, M. Mickler, A. Durham, S. Evans, E. Glatstein, S. Hahn, D. Fraker, K. Cengel, Preclinical evaluation of cetuximab and benzoporphyrin derivative-mediated intraperitoneal photodynamic therapy in a canine model, in: 35th American Society for Photobiology Providence, RI, 2010.
20. Savellano M.D., Hasan T. Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem. Photobiol. 2003, 77:431-439.
21. Savellano M.D., Hasan T. Photochemical targeting of epidermal growth factor receptor: a mechanistic study. Clin. Cancer Res. 2005, 11:1658-1668.
22. Mew D., Wat C.K., Towers G.H., Levy J.G. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J. Immunol. 1983, 130:1473-1477.
23. Duska L.R., Hamblin M.R., Bamberg M.P., Hasan T. Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br. J. Cancer 1997, 75:837-844.
24. Peng T.I., Chang C.J., Guo M.J., Wang Y.H., Yu J.S., Wu H.Y., Jou M.J. Mitochondrion-targeted photosensitizer enhances the photodynamic effect-induced mitochondrial dysfunction and apoptosis. Ann. NY Acad. Sci. 2005, 1042:419-428.
25. Sunada H., Magun B.E., Mendelsohn J., MacLeod C.L. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. USA 1986, 83:3825-3829.
26. Heitner T., Moor A., Garrison J.L., Marks C., Hasan T., Marks J.D. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J. Immunol. Methods 2001, 248:17-30.
27. Pogue B.W., Ortel B., Chen N., Redmond R.W., Hasan T. A photobiological and photophysical-based study of phototoxicity of two chlorins. Cancer Res. 2001, 61:717-724.
28. Runnels J.M., Chen N., Ortel B., Kato D., Hasan T. BPD-MA-mediated photosensitization in vitro and in vivo: cellular adhesion and beta1 integrin expression in ovarian cancer cells. Br. J. Cancer 1999, 80:946-953.
29. Savellano M.D., Pogue B.W., Hoopes P.J., Vitetta E.S., Paulsen K.D. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-A immunoconjugates. Cancer Res. 2005, 65:6371-6379.
30. Goff B.A., Bamberg M., Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res. 1991, 51:4762-4767.
31. Goff B.A., Hermanto U., Rumbaugh J., Blake J., Bamberg M., Hasan T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br. J. Cancer 1994, 70:474-480.
32. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23:1147-1157.
33. Lukan N., Strobel P., Willer A., Kripp M., Dinter D., Mai S., Hochhaus A., Hofheinz R.D. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 2009, 77:293-299.
34. Bernier J., Bentzen S.M., Vermorken J.B. Molecular therapy in head and neck oncology. Nat. Rev. Clin. Oncol. 2009, 6:266-277.
35. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
36. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.-R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359:1116-1127.
37. Koon H.K., Chan P.S., Wong R.N., Wu Z.G., Lung M.L., Chang C.K., Mak N.K. Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J. Cell. Biochem. 2009, 108:1356-1363.
38. Bhuvaneswari R., Gan Y.Y., Soo K.C., Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol. Cancer 2009, 8:94.
39. van Dongen G.A., Visser G.W., Vrouenraets M.B. Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv. Drug Deliv. Rev. 2004, 56:31-52.
40. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
41. Kessel D., Luo Y., Mathieu P., Reiners J.J. Determinants of the apoptotic response to lysosomal photodamage. Photochem. Photobiol. 2000, 71:196-200.
42. Berg K., Moan J. Lysosomes and microtubules as targets for photochemotherapy of cancer. Photochem. Photobiol. 1997, 65:403-409.
43. Tibbles L.A., Woodgett J.R. The stress-activated protein kinase pathways. Cell. Mol. Life Sci. 1999, 55:1230-1254.
44. Gille H., Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J. Biol. Chem. 1999, 274:22033-22040.
45. Fan Z., Lu Y., Wu X., Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 1994, 269:27595-27602.
46. Peng D., Fan Z., Lu Y., DeBlasio T., Scher H., Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996, 56:3666-3669.
47. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999, 286:1358-1362.
48. Cross T.G., Scheel-Toellner D., Henriquez N.V., Deacon E., Salmon M., Lord J.M. Serine/threonine protein kinases and apoptosis. Exp. Cell Res. 2000, 256:34-41.
49. Hayakawa J., Ohmichi M., Kurachi H., Kanda Y., Hisamoto K., Nishio Y., Adachi K., Tasaka K., Kanzaki T., Murata Y. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000, 60:5988-5994.
50. Ahmad N., Kalka K., Mukhtar H. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 2001, 20:2314-2317.
51. Del Governatore M., Hamblin M.R., Shea C.R., Rizvi I., Molpus K.G., Tanabe K.K., Hasan T. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. Cancer Res. 2000, 60:4200-4205.
52. Serebrovskaya E.O., Edelweiss E.F., Stremovskiy O.A., Lukyanov K.A., Chudakov D.M., Deyev S.M. Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein. Proc. Natl. Acad. Sci. USA 2009, 106:9221-9225.
53. Bhatti M., Yahioglu G., Milgrom L.R., Garcia-Maya M., Chester K.A., Deonarain M.P. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int. J. Cancer 2008, 122:1155-1163.
54. Vrouenraets M.B., Visser G.W., Loup C., Meunier B., Stigter M., Oppelaar H., Stewart F.A., Snow G.B., van Dongen G.A. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: a new possibility for use in photodynamic therapy. Int. J. Cancer 2000, 88:108-114.
55. Zhong W., Celli J.P., Rizvi I., Mai Z., Spring B.Q., Yun S.H., Hasan T. In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring. Br. J. Cancer 2009, 101:2015-2022.
56. Juarranz A., Jaen P., Sanz-Rodriguez F., Cuevas J., Gonzalez S. Photodynamic therapy of cancer. Basic principles and applications. Clin. Transl. Oncol. 2008, 10:148-154.
57. Beck T.J., Kreth F.W., Beyer W., Mehrkens J.H., Obermeier A., Stepp H., Stummer W., Baumgartner R. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg. Med. 2007, 39:386-393.
58. Stepp H., Beck T., Pongratz T., Meinel T., Kreth F.W., Tonn J., Stummer W. ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J. Environ. Pathol. Toxicol. Oncol. 2007, 26:157-164.
59. Savellano M.D., Hasan T. Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem. Photobiol. 2003, 77:431-439.